Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
- 18 December 2024 - 1 mins read
The purpose of this clinical research is to define the optimal uptake time of 68Ga-OPS202 as a PET imaging agent to be used to detect and localize breast cancer somatostatin receptor subtype 2 (SSTR2) positive lesions. 68Ga-OPS202 is a radiolabelled imaging agent to be used in association with PET. 68Ga-OPS202 is made of two main components: 1) OPS202, an antagonistic somatostatin analogue which binds to the somatostatin receptor (type 2) present on the surface of the tumor cells and 2) Gallium 68, a radioisotope that, combined with OPS202, can be seen in the PET scanner.
18 December 2024
1 mins read
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
18 December 2024
1 mins read
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
18 December 2024
1 mins read
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
18 December 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
18 December 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Follow-on Study
18 December 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Study
18 December 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Study
18 December 2024
1 mins read
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
18 December 2024
1 mins read
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
18 December 2024
1 mins read